Product
SYS6006
Aliases
20 μg dose of SYS6006, 30 μg dose of SYS6006
4 clinical trials
1 indication
Indication
COVID-19Clinical trial
A Phase I, Randomized, Observer-blinded, Placebo-controlled and Dose-escalation Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of a SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.Status: Active (not recruiting), Estimated PCD: 2022-07-09
Clinical trial
A Phase I, Randomized, Observer-blinded, Placebo-controlled and Dose-escalation Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 60 Years and Over.Status: Active (not recruiting), Estimated PCD: 2022-09-05
Clinical trial
A Randomized, Observer-blinded, Placebo-Controlled Phase 2 Clinical Study to Evaluate the Immunogenicity and Safety of a SARS-CoV-2 mRNA Vaccine (SYS6006) in Healthy Participants Aged 18 Years or MoreStatus: Active (not recruiting), Estimated PCD: 2023-01-12
Clinical trial
Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults Aged 18 Years or Above: a Multicenter, Parallel Groups, Partially Randomized, Open-label, Blank-controlled Adaptive Platform TrialStatus: Not yet recruiting, Estimated PCD: 2024-05-18